SUBSCRIBE
SUBSCRIBE

Alzheimer’s disease

Alzheimer's Report September 2019
Drug Development
Alzheimer’s Disease Insight Report: Current Therapies, Drug Pipeline and Outlook
50 million people worldwide live with symptomatic Alzheimer’s, which has no cure. In honor of September 21st being World Alzheimer’s Day, we evaluated the current therapies, drugs in the pipeline and disease outlook.
September 18, 2019
 · 
36 min read
 · 
Chelsea Weidman Burke, M.S.
Load More
PRESS RELEASES
Press Releases
Cassava Announces Publication of Peer-Reviewed Phase 3 Results for Simufilam in Alzheimer’s Disease in the Journal of Prevention of Alzheimer’s Disease
January 13, 2026
 · 
9 min read
Press Releases
Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease
January 13, 2026
 · 
6 min read
Press Releases
Alamar Biosciences Announces Launch of NULISAqpcr™ AD 5-plex Assay, Advancing Blood Based Biomarker Detection in Alzheimer’s Disease Research
January 13, 2026
 · 
2 min read
Press Releases
Global Alzheimer’s Platform Foundation Announces Strategic Collaboration and Partnership with Spear Bio for the Transformative Bio-Hermes-002 Study
January 13, 2026
 · 
3 min read
Press Releases
SciNeuro and Novartis Enter into a Licensing and Collaboration Agreement for Next Generation Therapeutics to Treat Alzheimer’s Disease
January 12, 2026
 · 
2 min read
Press Releases
Muna Therapeutics Awarded $1 Million Alzheimer’s Association Grant to Advance Clinical Development of Novel Oral TREM2 Agonist MNA-001 for Alzheimer’s
January 9, 2026
 · 
3 min read
Press Releases
Pramana Pharmaceuticals Awarded USD $1 Million from the Alzheimer’s Association
January 8, 2026
 · 
2 min read
Press Releases
Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program
January 6, 2026
 · 
4 min read
Press Releases
IGC Pharma Raises Capital to Advance IGC-AD1 Phase 2 Trial
January 5, 2026
 · 
3 min read
Press Releases
MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer’s Disease Psychosis
January 5, 2026
 · 
5 min read
Press Releases
Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer’s Disease Agitation
January 5, 2026
 · 
9 min read
Press Releases
Axsome Therapeutics Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for AXS-05 for the Treatment of Alzheimer’s Disease Agitation
January 1, 2026
 · 
7 min read
Press Releases
Longeveron, Selected as a StartUp Health Alzheimer’s Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026
December 29, 2025
 · 
5 min read
Press Releases
Tiziana Files Annual Safety Report for Intranasal Foralumab with FDA
December 29, 2025
 · 
5 min read
Press Releases
Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s Disease
December 24, 2025
 · 
4 min read
Press Releases
Quanterix Announces Landmark Nature Study Redefining Alzheimer’s Disease Neuropathology Prevalence
December 23, 2025
 · 
4 min read
Press Releases
Final, 247th participant randomized and commences treatment in Actinogen’s XanaMIA pivotal phase 2b/3 Alzheimer’s trial
December 19, 2025
 · 
8 min read
Press Releases
Tiziana Life Sciences Doses First Patient in Phase 2 Alzheimer’s Clinical Trial
December 18, 2025
 · 
5 min read
Press Releases
ADEL Signs $1.04 Billion Global License Agreement with Sanofi for ADEL-Y01, a Novel investigational Alzheimer’s Disease Therapy
December 16, 2025
 · 
2 min read
Press Releases
Tiziana Life Sciences to Dose First Patient in Phase 2 Alzheimer’s Trial
December 15, 2025
 · 
7 min read
Load More